Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Clin Lab ; 67(10)2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34655208

RESUMEN

BACKGROUND: The aim of this study was to determine the sensitivity and specificity of a novel immunochromatographic (IC) assay (APD1806) using monoclonal antibodies against the matrix (M) protein of human metapneumovirus (hMPV) for detection of hMPV from nasopharyngeal swab samples based on the results of real-time RT-PCR. METHODS: Nasopharyngeal swab samples taken from 189 patients aged 0 - 5 years who were suspected of having respiratory tract infections associated with hMPV were used in this study. The samples were tested both by the IC assay and by real-time RT-PCR for detection of hMPV. RESULTS: The sensitivity and specificity of the IC assay for detection of hMPV were 88.8% (95/107) and 92.7% (76/82), respectively. CONCLUSIONS: The IC assay using monoclonal antibodies against the M protein of hMPV is an accurate and fast assay that is suitable as a diagnostic tool for hMPV infection. The optimal timing of the IC assay is 12 hours or more after the onset of fever due to hMPV infection.


Asunto(s)
Metapneumovirus , Infecciones por Paramyxoviridae , Infecciones del Sistema Respiratorio , Proteínas de la Matriz Viral/inmunología , Anticuerpos Monoclonales , Humanos , Inmunoensayo , Lactante , Metapneumovirus/genética , Nasofaringe , Infecciones por Paramyxoviridae/diagnóstico , Infecciones del Sistema Respiratorio/diagnóstico
2.
Clin Lab ; 64(10): 1777-1781, 2018 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-30336514

RESUMEN

BACKGROUND: The aim of this study was to determine the sensitivity and specificity of a novel immunochromatographic assay (ICA) kit, ALSONIC® Adeno (Alfresa Pharma Co., Osaka, Japan), for the detection of human adenovirus (HAdV) from throat swab samples based on the results of real-time PCR. The incubation time required for the novel assay kit (5 minutes) is shorter than that required for other ICA kits that are available in Japan. METHODS: Throat swab samples were taken from 151 patients aged 6 months to 15 years who were suspected of having respiratory tract infections caused by HAdV. RESULTS: The sensitivity and specificity of the ICA for detection of HAdV were 92.2% (83/90) and 95.1% (58/61), respectively, and the assay showed positive and negative predictive values of 96.5% (83/86) and 89.2% (58/65), respectively. CONCLUSIONS: ALSONIC® Adeno is suitable as a diagnostic tool in the acute phase of HAdV infection.


Asunto(s)
Infecciones por Adenovirus Humanos/diagnóstico , Adenovirus Humanos/genética , Inmunoensayo/métodos , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones por Adenovirus Humanos/virología , Adenovirus Humanos/fisiología , Adolescente , Niño , Preescolar , ADN Viral/genética , Dosificación de Gen , Humanos , Inmunoensayo/instrumentación , Lactante , Faringe/virología , Juego de Reactivos para Diagnóstico , Reproducibilidad de los Resultados , Infecciones del Sistema Respiratorio/virología , Sensibilidad y Especificidad
3.
J Infect Chemother ; 24(6): 449-457, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29487035

RESUMEN

The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5-9 years was 2.13-times greater than that in patients aged 10-18 years (p = 0.012).


Asunto(s)
Ciclopentanos/administración & dosificación , Inhibidores Enzimáticos/administración & dosificación , Guanidinas/administración & dosificación , Gripe Humana/tratamiento farmacológico , Neuraminidasa/antagonistas & inhibidores , Oseltamivir/administración & dosificación , Zanamivir/análogos & derivados , Zanamivir/administración & dosificación , Ácidos Carbocíclicos , Adolescente , Niño , Preescolar , Ciclopentanos/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Femenino , Guanidinas/uso terapéutico , Humanos , Lactante , Recién Nacido , Virus de la Influenza A/efectos de los fármacos , Virus de la Influenza A/genética , Betainfluenzavirus/efectos de los fármacos , Betainfluenzavirus/genética , Japón , Masculino , Oseltamivir/uso terapéutico , Piranos , Estaciones del Año , Ácidos Siálicos , Resultado del Tratamiento , Zanamivir/uso terapéutico
4.
J Med Microbiol ; 70(6)2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-34165424

RESUMEN

We characterized 515 Mycoplasma pneumoniae specimens in Hokkaido. In 2013 and 2014, the p1 gene type 1 strain, mostly macrolide-resistant, was dominant and the prevalence of macrolide resistance was over 50 %. After 2017, the p1 gene type 2 lineage, mostly macrolide-sensitive, increased and the prevalence of macrolide resistance became 31.0 % in 2017, 5.3 % in 2018 and 16.3 % in 2019.


Asunto(s)
Macrólidos/farmacología , Mycoplasma pneumoniae/genética , Neumonía por Mycoplasma/epidemiología , Niño , Farmacorresistencia Bacteriana/genética , Técnicas de Genotipaje/métodos , Humanos , Japón/epidemiología , Mutación , Mycoplasma pneumoniae/clasificación , Mycoplasma pneumoniae/efectos de los fármacos , Nasofaringe/microbiología , Neumonía por Mycoplasma/tratamiento farmacológico , Neumonía por Mycoplasma/microbiología , ARN Ribosómico 23S/genética
5.
J Clin Microbiol ; 46(3): 928-32, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18174301

RESUMEN

A lateral-flow immunochromatography (IC) assay for the detection of human metapneumovirus (hMPV) has been developed by using two mouse monoclonal antibodies to the nucleocapsid protein of hMPV. The purpose of this study was to compare the virus detection rate in nasopharyngeal secretions by the IC assay with that by real-time reverse transcription-PCR (RT-PCR). We collected nasopharyngeal swab samples from 247 children with respiratory symptoms in Sapporo, Japan, during the period from April to July 2007. Sixty-eight of the 247 children were positive for hMPV by real-time RT-PCR. When the real-time RT-PCR was used as the reference standard, the IC assay results were positive for 48 of the 68 real-time RT-PCR-positive children (70.6% sensitivity) and 8 of the 179 real-time RT-PCR-negative children (95.5% specificity). Although the sensitivity of the IC assay is lower than that of real-time RT-PCR, the IC assay is a rapid and useful test for the diagnosis of hMPV infections in children.


Asunto(s)
Anticuerpos Monoclonales , Cromatografía/métodos , Metapneumovirus/aislamiento & purificación , Nasofaringe/virología , Infecciones por Paramyxoviridae/diagnóstico , Infecciones del Sistema Respiratorio/diagnóstico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Metapneumovirus/genética , Metapneumovirus/inmunología , Proteínas de la Nucleocápside/inmunología , Infecciones por Paramyxoviridae/virología , Infecciones del Sistema Respiratorio/virología , Sensibilidad y Especificidad , Factores de Tiempo
6.
PLoS One ; 12(3): e0173635, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28288170

RESUMEN

OBJECTIVE: To clarify therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia and against macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia in pediatric patients. METHODS: A prospective, multicenter observational study was conducted from July 2013 to August 2015. The therapeutic effects of azithromycin, clarithromycin, minocycline and tosufloxacin were evaluated in 59 patients with pneumonia caused by MRMP and in 50 patients with pneumonia caused by MSMP. In vitro activities of antimicrobial agents against isolates of Mycoplasma pneumoniae were also measured. RESULTS: Mean durations of fever following commencement of treatment in patients infected with MRMP and MSMP were 5.2 and 1.9 days, respectively (log-rank test, P < 0.0001). Among patients infected with MRMP, mean durations of fever were 4.6, 5.5, 1.0 and 7.5 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P < 0.0001). Among patients infected with MSMP, mean durations of fever were 2.5, 1.7, 0.9 and 4.3 days for patients treated with azithromycin, clarithromycin, minocycline and tosufloxacin, respectively (log-rank test, P = 0.0162). The MIC90s of azithromycin and clarithromycin among the 27 isolates of MRMP were 64 and 256 µg/ml, respectively, and those among the 23 isolates of MSMP were <0.000125 and 0.001 µg/ml, respectively. The MIC90s of minocycline and tosufloxacin among the 27 isolates of MRMP were 1.0 and 0.25 µg/ml, respectively, and those among the 23 isolates of MSMP were 1.0 and 0.5 µg/ml, respectively. CONCLUSION: Both minocycline and tosufloxacin showed good in vitro activities against MRMP. Minocycline, but not tosufloxacin, shortened the duration of fever in pediatric patients infected with MRMP compared to the duration of fever in patients treated with macrolides.


Asunto(s)
Antibacterianos/uso terapéutico , Mycoplasma pneumoniae/efectos de los fármacos , Neumonía por Mycoplasma/tratamiento farmacológico , Adolescente , Antibacterianos/farmacología , Azitromicina/uso terapéutico , Niño , Claritromicina/uso terapéutico , Farmacorresistencia Bacteriana/efectos de los fármacos , Femenino , Fluoroquinolonas/uso terapéutico , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Minociclina/uso terapéutico , Mycoplasma pneumoniae/genética , Naftiridinas/uso terapéutico , Neumonía por Mycoplasma/etiología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA